E. Anthony Figg and Jennifer Nock Shortlisted for 2021 LMG Life Sciences Americas Awards

Print PDF Icon

Partners E. Anthony Figg ("Tony") and Jennifer Nock ("Jen") are finalists in the ninth annual LMG Life Sciences Americas Awards. Tony is on the shortlist for Patent Strategy Attorney of the Year in the D.C. Metro area and Jen is on the shortlist for U.S. Rising Star in Intellectual Property. The LMG Life Sciences Awards is one of the most respected awards programs for life sciences practitioners and firms. Awardees are determined through a rigorous research process that aims to survey excellent legal service over a 12-month period and covers the four key practice areas surveyed by the LMG Life Sciences research team including regulatory, intellectual property, financial & corporate, and non-IP litigation & enforcement. 

Winners will be announced at the awards dinner on September 22, 2021, in New York.

In 2018, Tony was inducted into the LMG Life Sciences Hall of Fame at the 6th annual Life Sciences Awards. He and four other attorneys received this honor for their remarkable careers, dedication to clients, and influence on the industry. Tony specializes in intellectual property law, primarily involving the chemical, pharmaceutical, healthcare, and biotechnology industries. His practice focuses on patent litigation and inter partes matters before the PTAB, appeals, ADR, patent procurement, intellectual property licensing and related contract matters, opinions, and counseling.

Jen is experienced in a variety of patent matters including litigation, prosecution, licensing, opinions, and counseling. While she has experience working with patents in a wide range of technical fields, her practice is particularly focused on pharmaceuticals and biosimilars. She has worked on numerous Hatch-Waxman litigations, both in district court and on appeal to the Federal Circuit, as well as patent interferences and IPRs involving small molecules and biological products. Her practice also includes due diligence studies of pharmaceutical and biological patents for potential acquisitions.

Jump to Page

By using this site, you agree to our updated Privacy Policy and our Terms of Use.